## 2-(2-Cyanophenoxy)-N-[2-[cyclopropyl(oxo)methyl]-3-benzofuranyl]acetamide
This is a complex organic molecule with a rather long and specific chemical name. Its structure consists of multiple components:
* **2-cyanophenoxy**: A group derived from 2-cyanophenol, a compound with a cyano (CN) group attached to a benzene ring.
* **N-[2-[cyclopropyl(oxo)methyl]-3-benzofuranyl]acetamide**: This part involves a benzofuran ring (a fused aromatic system) with a cyclopropyl ketone group and an acetamide group attached.
The specific combination of these components results in a unique molecule with specific properties that might be valuable for research. However, without further context, it's difficult to know exactly why this particular compound is important.
**Possible research areas:**
* **Pharmaceutical research:** This molecule could be a potential drug candidate for treating certain diseases. The presence of different functional groups might give it specific pharmacological activities, such as inhibiting enzyme activity or interacting with receptors.
* **Materials science:** This molecule might exhibit unique properties that make it suitable for use in materials science applications, such as being used as a building block in polymers or as a component in electronic devices.
* **Analytical chemistry:** This compound might be used as a standard or reagent in analytical chemistry, especially if it has a unique spectroscopic signature (UV, IR, NMR).
**To understand the importance of this compound in research, we need more information:**
* **What is the purpose of the research?** (e.g., drug discovery, material development)
* **What specific properties of the compound are being investigated?** (e.g., biological activity, optical properties)
* **What are the results of the research?** (e.g., has the compound shown promise as a drug candidate, does it exhibit interesting material properties?)
Without this additional context, it's impossible to provide a definitive answer to why this specific compound is important for research.
ID Source | ID |
---|---|
PubMed CID | 654231 |
CHEMBL ID | 1377800 |
CHEBI ID | 105336 |
Synonym |
---|
2-(2-cyano-phenoxy)-n-(2-cyclopropanecarbonyl-benzofuran-3-yl)-acetamide |
MLS000033658 , |
smr000014220 |
CHEBI:105336 |
AKOS000506751 |
2-(2-cyanophenoxy)-n-[2-(cyclopropanecarbonyl)-1-benzofuran-3-yl]acetamide |
HMS2377J22 |
2-(2-cyanophenoxy)-n-[2-(cyclopropylcarbonyl)-1-benzofuran-3-yl]acetamide |
STL337135 |
2-(2-cyanophenoxy)-n-[2-[cyclopropyl(oxo)methyl]-3-benzofuranyl]acetamide |
bdbm62411 |
cid_654231 |
2-(2-cyanophenoxy)-n-(2-cyclopropylcarbonyl-1-benzofuran-3-yl)ethanamide |
2-(2-cyanophenoxy)-n-[2-(cyclopropanecarbonyl)benzofuran-3-yl]acetamide |
CHEMBL1377800 |
Q27183058 |
sr-01000320011 |
SR-01000320011-1 |
Class | Description |
---|---|
benzofurans | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 35.4813 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 63.0957 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 12.5893 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 39.8107 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0018 | 15.6638 | 39.8107 | AID894 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 6.3096 | 0.6561 | 9.4520 | 25.1189 | AID927 |
neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 12.5893 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 6.3096 | 1.5849 | 13.0043 | 25.1189 | AID927 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 8.9125 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
EBNA-1 protein [Human herpesvirus 4] | human gammaherpesvirus 4 (Epstein-Barr virus) | IC50 (µMol) | 11.0050 | 5.3520 | 5.4125 | 5.4730 | AID2381 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |